https://orcid.org/0000-0002-3633-5852
References
- Deeg HJ, Scott BL, Fang M, et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood. 2012;120(7):1398–1408.
- Yoshizato T, Nannya Y, Atsuta Y, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood. 2017;129(17):2347–2358.
- Yeung CCS, Gerds AT, Fang M, et al. Relapse after allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: Analysis of late relapse using comparative karyotype and chromosome genome array testing. Biol Blood Marrow Transplant. 2015;21(9):1565–1575.
- de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129(13):1753–1762.
- Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
- DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
- Ball BJ, Famulare CA, Stein EM, et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020;4(13):2866–2870.
- Azizi A, Asiri E, Ritika D, et al. Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leuk Lymphoma. 2020;61(11):2700–2707.
- Tobiasson M, McLornan DP, Karimi M, et al. Mutations in histone modulators are associated with prolonged survival during azacitidine therapy. Oncotarget. 2016;7(16):22103–22115.
- Cheson BD. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425.
- Amini R‐M, Ljungström V, Abdulla M, et al. Clonal hematopoiesis in patients with high-grade B-cell lymphoma is associated with inferior outcome. Am J Hematol. 2020;95(10):E287–E289.
- Tobiasson M, Pandzic T, Cavelier L, et al. Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1–azacitidine induces only lymphoma remission. Leuk Lymphoma. 2019;60(13):3316–3314.
- Compagno F, Basso S, Panigari A, et al. Management of PTLD after hematopoietic stem cell transplantation: Immunological perspectives. Front Immunol. 2020;11:567020.
- Sandhu KS, Sanjeet D, Dongyun Y, et al. Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2020;26(12):e322–e327.